Table 3.

Details about patients experiencing IRRs during rapid daratumumab infusion.

Patient	Age (years)	IRR at 1st standard infusion	Rapid infusion premedication	IRRs at rapid infusion	Outcome
1	64	Yes	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg, montelukast 10 mg	Erythema, dyspnea without desaturation	Rapid infusions discontinued
2	70	No	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg	Dyspnea with mild desaturation (sO2 91%), nasal congestion, throat irritation	Rapid infusions discontinued
3	79	No	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg	Dyspnea with mild desaturation (sO2 89%), nasal congestion, throat irritation	Rapid infusions discontinued
4	71	No	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg, montelukast 10 mg	Dyspnea, severe desaturation (sO2 70%), hypertension, tachycardia	Daratumumab permanently discontinued
5	68	Yes	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg	Headache, chest oppression with normal ECG parameters	Rapid infusions discontinued
6	65	No	Chlorpheniramine 10 mg, acetaminophen 1000 mg, dexamethasone 20 mg	Delayed (2 hours after the end of the infusion) nausea, vomiting and fatigue	Rapid infusions discontinued
7	64	Yes	Ranitidine 300 mg, chlorpheniramine 10 mg, methylprednisolone 60 mg, acetaminophen 1000 mg	Nausea and vomiting during the infusion	Rapid infusions continued

IRRs, infusion-related reactions; ECG, electrocardiogram.